Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name Youtube
Purpose External media

Pipeline

Preclinical drug development chain. Red arrows indicate the status of current projects in the lab.
© dkfz.de

The DKFZ – Bayer HealthCare Joint Laboratory focuses on the development of cancer therapeutics that enhance the reactivity of the patient’s immune system against the tumor. New targets for immunotherapeutics are identified by scientists at DKFZ and Bayer. After target validation, which generally takes place in the lab of the lead PI at DKFZ or Bayer, the projects are transferred to the Joint Lab for further pre-clinical development. The aim is to jointly develop new drugs towards clinical testing in phase I trials. Our current pipeline encompasses nine intra- and extracellular targets from which we are developing small molecules and antibody therapeutics, respectively.

to top
powered by webEdition CMS